Bioactor and Ferrerhealthtech have announced the signature of a Collaboration Agreement to jointly develop and market Bioactor’s innovative cardiovascular ingredient – cordiart – in the Americas. Under this Agreement, parties will collaborate on additional clinical validation of cordiart and pool resources to market and sell cordiart in the Americas.
Thanks to its proprietary process technology Ferrer HealthTech will custom-manufacture and exclusively supply cordiart to Bioactor.
Cordiart, a specific rutinoside formulation for cardiovascular health, has shown strong clinical data on the improvement of endothelial function. Parties have completed a pharmacokinetics study showing the high bioavailability of cordiart.
Bioactor and Ferrer HealthTech are co-financing a robust research programme on additional health effects of certain citric flavonoids in the course of which at least 3 additional clinical studies will be performed. Hans van der Saag, Managing Director of Bioactor comments; our joint clinical research programme, further complemented by our participation in the EU BACCHUS Project, constitutes one of the largest research endeavors in the polyphenols space.
Tom D’hoore, Area Manager of Ferrer HealthTech : “Bioactor’s scientific excellence and intellectual property perfectly complements Ferrer HealthTech ’s expertise in polyphenols. Moreover, the agreement strengthens our value proposition to our customers in North and South America “.
Hans van der Saag, Managing Director of Bioactor comments: “we are delighted to be working with Ferrer HealthTech and believe this partnership will expedite the successful market introduction of cordiart, a first in class ingredient to support healthy blood circulation”. Arterial dysfunction is becoming an increasing health burden, affecting millions of people. Public health authorities have recognized the need for prevention of this chronic disease. Functional/medical foods and dietary supplements addressing cardiovascular health are seen as an excellent solution for long-term prevention. Bioactoris addressing this need by developing a unique product for endothelial health – cordiart. Cordiart stimulates the eNOS-enzyme which plays a pivotal role in the synthesis of Nitric Oxide, one of the most important regulators of vascular elasticity.
BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bioactives that address the metabolic syndrome and ageing related chronic health conditions. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Ferrer HealthTech, based in Barcelona, is the ingredients division of the pharmaceutical group Ferrer. The company specializes in polyphenols for health improvement and taste modulation. Ferrer HealthTech serves customers worldwide in the pharma, food, health food and cosmetic industry.
